GlobalPost reports on the GBCHealth Conference, which took place in New York City on Monday and where “panelists at a session titled ‘AIDS@30’ were asked how they would fulfill U.S. Secretary of State Hillary Clinton’s call late last year for an ‘AIDS-free generation.'” According to the news service, “Ambassador Eric Goosby, the U.S. global AIDS coordinator, said the key will likely be a combination HIV prevention strategy” that “includes expansion of treatment to help prevent new infections; major scale-up of male circumcision; and treating all HIV-positive pregnant women to end the transmission of HIV from mother to child.” GlobalPost adds, “Michel Sidibe, UNAIDS executive director, said the way to defeat AIDS had to include more financial contributions from developing countries.” GlobalPost quotes several other conference attendees (Donnelly, 5/15).
Private Sector Involvement
With nearly 6,000 reported cholera cases, including more than 100 deaths, Guinea is facing the worst cholera outbreak since 2007, and “some residents of the capital Conakry are clamoring to be vaccinated,” IRIN reports. “The cholera vaccine has shown promising results in the handful of communities where it has been used: none of those vaccinated have been infected,” the news service writes, noting, “For now cholera vaccination is not generally done on a large scale.” According to IRIN, “WHO and partner agencies are planning a cholera vaccine stockpile for epidemic control and looking at the possibility of introducing the two-dose oral vaccine into national immunization programs in endemic areas,” but the agency also “says such stockpiles should not detract from other prevention efforts: detection, diagnosis, and treatment of cases with oral rehydration and antibiotics; establishment of a safe water supply; implementation of adequate waste disposal, sanitation, and hygiene; and communication and social mobilization.”
The Affordable Medicines Facility-malaria (AMFm) — an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria — “brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011” and “also increased access to the top malaria medicines by 26 to 52 percent in six countries,” according to results from the first phase of the program, which is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, NPR’s “Shots” blog reports. The results of the evaluation, released on Wednesday in Washington, D.C., do not estimate how many lives were saved because of improved access to effective malaria medications, as “AMFm ran for only a year and half in most countries,” according to the blog. “The AMFm negotiated with drugmakers to reduce ACTs prices, and then the Global Fund subsidized the initial purchasing of the drugs by clinics and pharmacies,” the blog notes.
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
The first-ever results from a dengue virus vaccine clinical trial aimed at showing effectiveness “provide signals rather than definitive answers, and a mixture of both promise and unresolved challenges,” Orin Levine, executive director of the International Vaccine Access Center, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in the Huffington Post “Impact” blog. “To date, these represent the most promising indications that a safe, effective vaccine to prevent dengue is technically feasible,” they continue, adding, “At the same time, the results on protection were inconclusive, somewhat inconsistent with the measured immune responses and uneven across the four strains included in the vaccine.”
Noting the Copenhagen Consensus has stated that “large-scale micronutrient fortification is a proven and cost-effective intervention that can mitigate malnutrition in the form of vitamin and mineral deficiencies and enhance the well-being of millions,” Marc Van Ameringen, executive director of the Global Alliance for Improved Nutrition (GAIN), writes in the Huffington Post “Impact” blog, “On September 9, 2012, [GAIN] launched a partnership in Kabul with Afghanistan’s Ministry of Public Health, the Khalifa Bin Zayed Al Nahyan Foundation (KBZF) and the World Food Programme (WFP) to help alleviate the burden of malnutrition in Afghanistan by bringing more nutritious wheat flour, vegetable oil, and ghee to approximately half of the country’s population.”
The Coca-Cola Company and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the expansion of a pilot project, called “Project Last Mile,” that uses Coca Cola’s “‘expansive global distribution system and core business expertise’ to help deliver critical medicines to remote parts of the world, beginning in rural Africa,” Pharma Times reports. “The public-private partnership was established in 2010 to help Tanzania’s government-run medicine distribution network, Medical Stores Department, build a more efficient supply chain by using Coca-Cola’s” delivery system model, the news service writes, adding, “The latest phase of the partnership, developed in cooperation with the likes of the Bill & Melinda Gates Foundation, Accenture and Yale University, will increase the availability of critical medicines to 75 percent of Tanzania and expand the initiative to Ghana and Mozambique” (Grogan, 9/26).
“India has had a positive global impact through its supply of vast quantities of low-cost, good-quality generic medicines, which have saved or prolonged millions of lives … [b]ut there are also many factors that may hinder the continuation of the [country’s] role as chief supplier of medicines to developing countries,” Martin Khor, executive director of the South Centre in Geneva, writes in an Inter Press Service opinion piece. He examines the history of generic drug production in India and says the 1995 World Trade Organization TRIPS agreement negatively affected the country’s ability to produce generic drugs. Though “India has one of the best patent laws in the world that still gives some space to its producers to make generic drugs, … it is also true that the old policy space has been eroded because many new drugs have, since 2005, been patented by multinational companies that are selling them at exorbitant prices,” Khor writes.
The Hill’s “Congress Blog” on Friday published two opinion pieces addressing global food security, the G8 summit, and the New Alliance for Food and Nutrition Security. The following are summaries of the pieces.
In a Symposium on Global Agriculture and Food Security on Friday, President Barack Obama “announced a plan to accelerate investments in developing world agriculture to meet rising food demands and improve nutrition, calling the New Alliance for Food Security and Nutrition a moral, economic and security imperative,” IIP Digital reports (Porter, 5/18). The new program, unveiled “in conjunction with African leaders from Ethiopia, Ghana and Tanzania, will parlay more than $3 billion in private assistance into a public-private partnership with an ambitious goal: lifting 50 million people from poverty over 10 years,” according to USA Today’s “The Oval” (Wolf, 5/18). The initiative “will constitute the next phase of a groundbreaking program begun during the 2009 G8 summit in L’Aquila, Italy,” Inter Press Service writes (Brion, 5/18). More than 45 companies have pledged to invest in the initiative, Devex notes (Ravelo, 5/10). A fact sheet on the New Alliance is available on the White House website (5/18).